Dare Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Daré Bioscience reports Q1 progress in women's health innovation

Daré Bioscience showcased progress in Q1 2024 with achievements in product commercialization and pipeline advancements, despite a reported comprehensive loss.
The company's focus on women's health innovation and commitment to driving value for stakeholders position them well for future growth.
While facing financial challenges and competitive pressures, Daré Bioscience has opportunities to capitalize on its strong pipeline and attract investor interest.
Continued momentum in Phase III studies and technology development present avenues for growth and market expansion in the women's health sector.

Dare Bioscience reports strong Q2 earnings, advances women's health therapies

Dare Bioscience delivered a robust Q2 2024 performance marked by cost efficiencies, revenue generation from strategic transactions, and progress in key product developments.
The company's focus on women's health and commitment to advancing therapies position it well for future growth and market leadership in a segment with significant unmet needs.
While facing challenges in market adoption and regulatory interactions, Dare Bioscience has opportunities to drive revenue growth, expand its market presence, and diversify its product portfolio.
Overall, Dare Bioscience's Q2 earnings call reflects a company on a positive trajectory, with a strong financial foundation and a strategic focus on advancing innovative solutions for women's health.

Daré Bioscience reports cost reductions and promising pipeline developments

Daré Bioscience showcased strong financial discipline with notable expense reductions and strategic funding acquisitions, positioning the company for sustainable growth.
Progress in late-stage candidates and FDA interactions signals promising developments in the pipeline, underscoring Daré's commitment to innovation in women's health.
While facing financial challenges and operational hurdles, Daré's focus on disruptive products and leveraging funding opportunities presents avenues for future success.
Overall, Daré Bioscience's Q3 performance reflects a balance of cost management, innovation, and strategic positioning in the healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q2 2021 Results - Earnings Call Transcript

Conference Call and Webcast Today at 4:30 p.m. Eastern Time Conference Call and Webcast Today at 4:30 p.m. Eastern Time

Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

The FDA has accepted for review Daré Bioscience Inc's (NASDAQ: DARE) marketing application for DARE-BV1 for bacterial vaginosis. Under the priority review, the target goal date is December 7.

Daré Bioscience Stock Is Trading Higher As Bacterial Vaginosis Candidate Secures FDA Priority Review

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 12, 2021, to review its financial results for the quarter ended June 30, 2021 and to provide a Company update.

Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021

Amarin Corporation Plc

Borqs Technologies

Looking for penny stocks to watch in the second half of 2021? Check these 3 out The post Best Penny Stocks to Buy?

Best Penny Stocks to Buy? 3 to Watch In the Second Half of 2021

ConforMIS

Color Star Technology

Which Penny Stocks Are Investors Watching As August Gets Off to a Strong Start? The post Top Penny Stocks to Watch to Start Your Week Off Right  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch to Start Your Week Off Right

Presentation will highlight the positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating Daré's product candidate DARE-BV1 in women diagnosed with bacterial vaginosis

Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

Castor Maritime Inc

Express

Which penny stocks are traders watching after yesterday's market selloff? The post High Volume Penny Stocks to Watch After The Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

High Volume Penny Stocks to Watch After The Market Crash

Funding and Clinical Operations Support will be Provided by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Under the CRADA

Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive

The stock price of Dare Bioscience Inc (NASDAQ: DARE) increased 23.68% yesterday. This is why it happened.

Dare Bioscience Stock Increased 23.68%: Why It Happened

ARCA biopharma

BioDelivery Sciences

G Medical Innovations Holdings Ltd

Jaguar Health

Luokung Technology Corp

Exela Technologies

Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?

Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List

Dare Bioscience (DARE) stock is rising higher on Wednesday after revealing a $48.95 million grant from the Bill & Melinda Gates Foundation. The post DARE Stock: Why Did ‘Gates' Give Dare Bioscience a $49M Grant?

DARE Stock: Why Did ‘Gates' Give Dare Bioscience a $49M Grant?

In a regulatory 8-K filing, on June 30, Dare Bioscience Inc (NASDAQ: DARE) entered into an agreement with the Bill & Melinda Gates Foundation for a new grant of up to $48.95 million for DARE-LARC1, its investigational user-controlled, long-acting reversible contraceptive. The Grant will support technology development and preclinical activities to advance DARE-LARC1 toward clinical testing in humans from June 30 to November 1, 2026.

Why Dare Bioscience (DARE) Stock Trading Higher On Wednesday?

The stock price of Dare Bioscience Inc (NASDAQ: DARE) increased by over 25% pre-market. This is why it happened.

Dare Bioscience Stock Increases Over 25% Pre-Market: Why It Happened

Second Sight Medical Products

GT Biopharma Inc

Predictive Oncology Inc

Current & former penny stocks to watch if you like biotech right now. The post Best Penny Stocks For Your July 2021 List?

Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now

Daré Bioscience Inc (NASDAQ: DARE) has announced positive topline results from its Phase 1 trial of DARE-HRT1 as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and bio-identical progesterone.

Daré Bioscience's DARE-HRT1 Shows Potential As Monthly Therapy For Vasomotor, Vaginal Symptoms of Menopause

Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1

Daré Bioscience's (DARE) CEO Sabrina Martucci Johnson on Q1 2021 Results - Earnings Call Transcript

Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 13, 2021, to review its financial results for the quarter ended March 31, 2021 and to provide a Company update.

Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that data from the Company's postcoital test (PCT) clinical study of its novel investigational hormone-free monthly intravaginal contraceptive, Ovaprene, will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting. The meeting will be conducted virtually from April 30 - May 2, 2021.

Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2020 Results - Earnings Call Transcript

Shares of Dare Bioscience (NASDAQ:DARE) decreased 2.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 4.76% year over year to ($0.22), which missed the estimate of ($0.13).

Dare Bioscience: Q4 Earnings Insights

Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update

Topline data readout targeted for year-end 2021 Topline data readout targeted for year-end 2021

News for Dare Bioscience Stock (DARE)